Literature DB >> 28098887

miRNA‑375 regulates the cell survival and apoptosis of human non‑small cell carcinoma by targeting HER2.

Longqiang Cheng1, Bingxiang Zhan1, Peng Luo1, Baolong Wang1.   

Abstract

micro (mi)‑RNAs are a class of small non‑coding RNAs that regulate gene expression by binding to the 3'‑untranslated region of mRNA, which may lead to mRNA degradation or transcription regulation. Previous studies indicated that miRNAs are important for the pathogenesis of human cancer. miR‑375 has been implicated in various tumor types; however, the biological activity in human non‑small cell lung carcinoma (NSCLC) cells remains to be fully elucidated. The purpose of the present study was to investigate the biological importance of miR‑375 in human NSCLC cells. The expression of miRNAs and mRNA was determined using reverse transcription‑quantitative polymerase chain reaction. Cell proliferation was analyzed using a Cell Counting kit‑8 assay. Cell apoptosis was analyzed using a fluorescence‑activated cell sorting assay. The migration and invasion abilities of cells were evaluated using an in vivo mouse model. Dual‑luciferase assay and western blotting were used to determine the potential target of miR‑375. The results indicated that the expression of miR‑375 in human NSCLC cells was significantly downregulated and induction of miR‑375 may inhibit the proliferation of human NSCLC cells by inducing apoptosis. An animal model was used to determine that the upregulation of miR‑375 inhibited the migration and invasion of A549 human NSCLC cells in vivo. It was also determined that human epidermal growth factor receptor 2 (HER‑2) was a direct target gene of miR‑375 and induction of miR‑375 may reduce the expression of HER‑2 in human NSCLC cells. These findings suggested that miR‑375 may act as a potential therapeutic target for human NSCLC cancer in the future.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28098887     DOI: 10.3892/mmr.2017.6112

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  Long non-coding RNA LUCAT1 promotes the progression of clear cell renal cell carcinoma via the microRNA-375/YAP1 axis.

Authors:  Xiaojun Wang; Hui Ou; Liangfen Zhou; Hengyu Liu; Xiaobao Liu; Huiyun Zhang
Journal:  Exp Ther Med       Date:  2021-05-12       Impact factor: 2.447

2.  MicroRNA‑30a regulates cell proliferation, migration, invasion and apoptosis in human nasopharyngeal carcinoma via targeted regulation of ZEB2.

Authors:  Xi Chen; Junzheng Li; Shifen Zhang; Weiping Xu; Dianyu Shi; Mugai Zhuo; Shaoqin Liang; Wenbin Lei; Chun Xie
Journal:  Mol Med Rep       Date:  2019-06-14       Impact factor: 2.952

3.  microRNA-211 regulates cell proliferation, apoptosis and migration/invasion in human osteosarcoma via targeting EZRIN.

Authors:  Yihua Pei; Qin Yao; Yingchao Li; Xin Zhang; Bozhen Xie
Journal:  Cell Mol Biol Lett       Date:  2019-07-09       Impact factor: 5.787

4.  The Reciprocal Interaction Between LncRNA CCAT1 and miR-375-3p Contribute to the Downregulation of IRF5 Gene Expression by Solasonine in HepG2 Human Hepatocellular Carcinoma Cells.

Authors:  Zheng Liu; ChangJu Ma; XiaoJuan Tang; Qing Tang; LiJie Lou; Yaya Yu; Fang Zheng; JingJing Wu; Xiao-Bo Yang; Wei Wang; Swei Sunny Hann
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

5.  miR-381 Inhibits Proliferation and Invasion of Non-Small-Cell Cancer Cells by Targeting USP39.

Authors:  Fang Cui; Peng Luo; Rui Wu; Jiangping Meng
Journal:  Dis Markers       Date:  2022-08-21       Impact factor: 3.464

Review 6.  The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer.

Authors:  Michał Szczyrek; Paulina Bitkowska; Marta Jutrzenka; Janusz Milanowski
Journal:  J Pers Med       Date:  2022-07-27

7.  MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC.

Authors:  ZiJun Liao; Qi Zheng; Ting Wei; YanBing Zhang; JieQun Ma; Zheng Zhao; HaiFeng Sun; KeJun Nan
Journal:  Oncol Res       Date:  2019-11-11       Impact factor: 5.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.